|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
4262578 |
| 003 |
ICU |
| 005 |
20030529231500.0 |
| 008 |
000428s2000 njua b 001 0 eng d |
| 010 |
|
|
|a 99088373
|
| 020 |
|
|
|a 0896037355 (alk. paper)
|
| 035 |
|
|
|a CTYAFMZ3005-B
|
| 035 |
|
|
|a (CtY)notisFMZ3005
|
| 035 |
|
|
|a 90059866
|
| 040 |
|
|
|a CtY-M
|c CtY-M
|d OrLoB-B
|d OCoLC
|
| 082 |
0 |
0 |
|a 615/.372 dc21
|
| 245 |
1 |
0 |
|a Vaccine adjuvants :
|b preparation methods and research protocols /
|c edited by Derek T. O'Hagan.
|
| 260 |
|
|
|a Totowa, N.J. :
|b Humana Press,
|c 2000.
|
| 300 |
|
|
|a x, 342 p :
|b ill. ;
|c 24 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 440 |
|
0 |
|a Methods in molecular medicine
|v v 42.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|g 1.
|t An Overview of Adjuvant Use /
|r Robert Edelman --
|g 2.
|t Harmful and Beneficial Activities of Immunological Adjuvants /
|r Duncan E. S. Stewart-Tull --
|g 3.
|t Freund's Adjuvants /
|r Erick B. Lindblad --
|g 4.
|t Aluminum Compounds as Vaccine Adjuvants /
|r Rajesh K. Gupta and Bradford E. Rost --
|g 5.
|t Poly(Lactide-Coglycolide) Microparticles As Vaccine Adjuvants /
|r Derek T. O'Hagan and Manmohan Singh --
|g 6.
|t Poly(Methyl Methacrylate) Nanoparticles as Vaccine Adjuvants /
|r Jorg Kreuter --
|g 7.
|t Aqueous Formulation of Adjuvant-Active Nonionic Block Copolymers /
|r Charles W. Todd and Mark J. Newman --
|g 8.
|t Liposomes As Immunological Adjuvants and Vaccine Carriers /
|r Gregory Gregoriadis, Brenda McCormack and Mia Obrenovic /
|r [et al.] --
|g 9.
|t Immunopotentiating Reconstituted Influenza Virosomes (IRIVs) /
|r Reinhard Gluck --
|g 10.
|t Cochleates for Induction of Mucosal and Systemic Immune Responses /
|r Susan Gould-Fogerite and Raphael J. Mannino --
|g 11.
|t Virus-like Particles As Vaccine Adjuvants /
|r Sarah C. Gilbert --
|g 12.
|t The Adjuvant MF59: A 10-Year Perspective /
|r Gary Ott, Ramachandran Radhakrishnan and Jia-Hwa Fang /
|r [et al.] --
|g 13.
|t Preparation of the Syntex Adjuvant Formulation (SAF, SAF-m, and SAF-1) /
|r Deborah M. Lidgate --
|g 14.
|t The ISCOM Technology /
|r Karin Lovgren-Bengtsson and Bror Morein --
|g 15.
|t QS-21 Adjuvant /
|r Charlotte Read Kensil --
|g 16.
|t MPL Immunostimulant: Adjuvant Formulations /
|r J. Terry Ulrich --
|g 17.
|t Cytokines As Vaccine Adjuvants: The Use of Interleukin-2 /
|r Martin A. Giedlin --
|g 18.
|t DNA As an Adjuvant /
|r David C. Neujahr and David S. Pisetsky --
|g 19.
|t Transcutaneous Immunization /
|r Gregory M. Glenn, Tanya Scharton-Kersten and Russell Vassell --
|g 20.
|t Mutant Heat-Labile Enterotoxins As Adjuvants for CTL Induction /
|r Jason A. Neidleman, Gary Ott and Derek O'Hagan.
|
| 650 |
|
0 |
|a Immunological adjuvants.
|0 http://id.loc.gov/authorities/subjects/sh85000895
|
| 650 |
|
0 |
|a Vaccines.
|0 http://id.loc.gov/authorities/subjects/sh85141718
|
| 650 |
1 |
2 |
|a Vaccines
|x immuniology.
|
| 650 |
2 |
2 |
|a Adjuvants, Immunologic.
|
| 650 |
|
7 |
|a Immunological adjuvants.
|2 fast
|0 http://id.worldcat.org/fast/fst00967992
|
| 700 |
1 |
|
|a O'Hagan, Derek T.
|0 http://id.loc.gov/authorities/names/n93804460
|1 http://viaf.org/viaf/54255508
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 903 |
|
|
|a Hathi
|
| 035 |
|
|
|a (OCoLC)43051471
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i 5a0837b6-38bc-519d-941d-95e7dffcd1e9
|s 286cf6c4-5939-54ed-b62f-d1dda56f1ae5
|
| 928 |
|
|
|t Library of Congress classification
|a QR187.3 .V33 2000
|l JCL
|c JCL-Sci
|i 4241729
|
| 927 |
|
|
|t Library of Congress classification
|a QR187.3 .V33 2000
|l JCL
|c JCL-Sci
|e CRERAR
|b 55955292
|i 6823773
|
